LY 3325656

Drug Profile

LY 3325656

Alternative Names: LY-3325656

Latest Information Update: 27 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 31 May 2017 Phase-I clinical trials in Type-2 diabetes mellitus (Combination therapy, In adults, In the elderly) in Singapore (PO) (NCT03115099)
  • 31 May 2017 Phase-I clinical trials in Type-2 diabetes mellitus (In the elderly, In adults, Monotherapy) in Singapore (PO) (NCT03115099)
  • 19 Apr 2017 Preclinical trials in Type-2 diabetes mellitus in Singapore(NCT03115099) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top